Use of [ 11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression

Clinical Cancer Research

Volumn 17, Issue 24, 2011, Pages 7673-7683

  Contractor, Kaiyumars ^a   Challapalli, Amarnath ^a   Barwick, Tara ^b   Winkler, Mathias ^a   Hellawell, Giles ^a   Hazell, Steve ^b   Tomasi, Giampaolo ^a   Al Nahhas, Adil ^b   Mapelli, Paola ^a   Kenny, Laura M ^a   Tadrous, Paul ^c   Coombes, R Charles ^a   Aboagye, Eric O ^a   Mangar, Stephen ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

^c EALING HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CHOLINE C 11; CHOLINE KINASE; CHOLINE KINASE ALPHA; KI 67 ANTIGEN; UNCLASSIFIED DRUG; CARBON; CHOLINE; DIAGNOSTIC AGENT;

ABDOMINAL RADIOGRAPHY; ADJUVANT THERAPY; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SIZE; CANCER STAGING; CELL NUCLEUS; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYTOPLASM; DIAGNOSTIC TEST ACCURACY STUDY; DRUG DISTRIBUTION; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAPAROSCOPIC SURGERY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS LYMPH NODE; PELVIS RADIOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOLOGICAL PARAMETERS; SENSITIVITY AND SPECIFICITY; STANDARDIZED UPTAKE VALUE; BIOSYNTHESIS; ENZYMOLOGY; LIMIT OF DETECTION; LYMPH NODE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PELVIS; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR; RADIOGRAPHY; REPRODUCIBILITY; SCINTISCANNING;

AGED; AGED, 80 AND OVER; CARBON RADIOISOTOPES; CHOLINE; CHOLINE KINASE; HUMANS; IMMUNOHISTOCHEMISTRY; LIMIT OF DETECTION; LYMPH NODES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PELVIS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 84055176511     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2048     Document Type: Article

References (45)

1. Danella JF, deKernion JB, Smith RB, Steckel J. The contemporary incidence of lymph node metastases in prostate cancer: implications for laparoscopic lymph node dissection. J Urol 1993;149:1488-91. (Pubitemid 23164552)
2. Leibel SA, Fuks Z, Zelefsky MJ, Whitmore WF Jr. The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 1994;28:7-16. (Pubitemid 24012849)
3. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neoadjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006:CD006019.
4. Robnett TJ, Whittington R, Malkowicz SB, Brereton HD, Van Arsdalen K, Drach G, et al. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:1146-51. (Pubitemid 34787849)
5. Stone NN, Stock RG. Laparoscopic pelvic lymph node dissection in the staging of prostate cancer. Mt Sinai J Med 1999;66:26-30.
6. Allaf ME, Partin AW, Carter HB. The importance of pelvic lymph node dissection in men with clinically localized prostate cancer. Rev Urol 2006;8:112-9.
7. Wyler SF, Sulser T, Seifert HH, Ruszat R, Forster TH, Gasser TC, et al. Laparoscopic extended pelvic lymph node dissection for high-risk prostate cancer. Urology 2006;68:883-7. (Pubitemid 44633375)
8. Parkin J, Keeley FX Jr, Timoney AG. Laparoscopic lymph node sampling in locally advanced prostate cancer. BJU Int 2002;89:14-7; discussion 7-8.
9. Jager GJ, Barentsz JO, Oosterhof GO, Witjes JA, Ruijs SJ. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol 1996;167:1503-7. (Pubitemid 26418741)
10. Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008;63:387-95.
11. Rorvik J, Halvorsen OJ, Albrektsen G, Haukaas S. Lymphangiography combined with biopsy and computer tomography to detect lymph node metastases in localized prostate cancer. Scand J Urol Nephrol 1998;32:116-9. (Pubitemid 28206804)
12. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491-9. (Pubitemid 36706536)
13. Bernd H, De Kerviler E, Gaillard S, Bonnemain B. Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program. Invest Radiol 2009;44:336-42.
14. Roy C, Bierry G, Matau A, Bazille G, Pasquali R. Value of diffusion-weighted imaging to detect small malignant pelvic lymph nodes at 3 T. Eur Radiol 2010;20:1803-11.
15. Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 1996;155:994-8.
16. Hain SF. Positron emission tomography in uro-oncology. Cancer Imaging 2005;5:1-7.
17. Hoh CK, Seltzer MA, Franklin J, deKernion JB, Phelps ME, Belldegrun A. Positron emission tomography in urological oncology. J Urol 1998;159:347-56. (Pubitemid 28049232)
18. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990-5. (Pubitemid 28270113)
19. Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D, et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 2006;47:1249-54. (Pubitemid 47544875)
20. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, Bonilla F, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002;296:580-3.
21. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001;61:3599-603. (Pubitemid 32694969)
22. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;59:80-4. (Pubitemid 29062961)
23. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004;64:4270-6. (Pubitemid 38802433)
24. Leyton J, Smith G, Zhao Y, Perumal M, Nguyen QD, Robins E, et al. 18F]fluoromethyl-[1,2-2H4]-choline: a novel radiotracer for imaging choline metabolism in tumors by positron emission tomography. Cancer Res 2009;69:7721-8.
25. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003;44:331-5. (Pubitemid 39586006)
26. Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000;27:1415-9.
27. Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A, et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008;54:392-401.
28. Pascali C, Bogni A, Itawa R, Cambiè M, Bombardieri E. [11C]Methylation on a C18 Sep-Pak cartridge: a convenient way to produce [N-methyl-11C]choline. J Labelled Comp Rad 2000;43:195-203. (Pubitemid 30072211)
29. Hawass NE. Comparing the sensitivities and specificities of two diagnostic procedures performed on the same group of patients. Br J Radiol 1997;70:360-6.
30. Kenny LM, Contractor KB, Hinz R, Stebbing J, Palmieri C, Jiang J, et al. Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab. Clin Cancer Res 2010;16:4236-45.
31. Kwee SA, Coel MN, Lim J, Ko JP. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol 2005;173:252-5. (Pubitemid 39627729)
32. Yamaguchi T, Lee J, Uemura H, Sasaki T, Takahashi N, Oka T, et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 2005;32:742-8. (Pubitemid 41125415)
33. Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005;46:1642-9. (Pubitemid 46211588)
34. Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumor stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008;35:1065-73.
35. Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E, et al. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006;176:954-60; discussion 60.
36. Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker HC, et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007;34:45-53. (Pubitemid 44885553)
37. Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, et al. 18F choline PET/CTin the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010;254:925-33.
38. Hacker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W, et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2006;176:2014-8; discussion 8-9.
39. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:253-63.
40. Hricak H, Dooms GC, Jeffrey RB, Avallone A, Jacobs D, Benton WK, et al. Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 1987;162:331-6. (Pubitemid 17015632)
41. Clements R. Imaging in prostate cancer. 2010 [cited; Available from: http://emedicine.medscape.com/article/379996-overview.
42. Al-Saeedi F, Welch AE, Smith TA. [methyl-3H]Choline incorporation into MCF7 tumor cells: correlation with proliferation. Eur J Nucl Med Mol Imaging 2005;32:660-7. (Pubitemid 40897488)
43. Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res 2002;62:1966-70. (Pubitemid 34408439)
44. Ramirez de Molina A, Banez-Coronel M, Gutierrez R, Rodriguez-Gonzalez A, Olmeda D, Megias D, et al. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res 2004;64:6732-9. (Pubitemid 39297936)
45. Piert M, Park H, Khan A, Siddiqui J, Hussain H, Chenevert T, et al. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med 2009;50:1585-93.